Allogene Therapeutics Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Hungarian Gripen jet crashes, no injuries reported, PM Magyar says
Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 9c
August 9, 2022 4:15 PM EDTAllogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.52), $0.09 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $86 thousand versus the consensus estimate of $8.33 thousand.
For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.
... More